Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?
Open Access
- 1 January 2012
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Acta Endocrinologica
- Vol. 166 (1), 21-26
- https://doi.org/10.1530/eje-11-0738
Abstract
Background Somatostatin analogs (SA) have been used for over 25 years in the treatment of acromegaly. A major disadvantage is the need to continue therapy indefinitely. Objective To evaluate the feasibility of discontinuing therapy in well-controlled patients with acromegaly treated chronically with SA. Design and methods Of the 205 subjects on octreotide LAR, we selected those who met the following criteria: two or more years of treatment, a stable dose and injection interval of 20 mg every 8 weeks or longer for the previous year, no history of radiation, no cabergoline for the previous 6 months, a GH Results Twelve patients (ten women, mean age 48±13 years) were studied. Seven patients (58.3%) relapsed biochemically within 1 year of having stopped the SA; two patients relapsed by GH and IGF1 criteria, the remaining five patients kept GH levels within target. Five patients (41.7%) remain in remission after 12 months of follow-up. Non-recurring patients were on longer injection intervals but no other characteristic was associated with a successful withdrawal. Conclusion Withdrawal of SA is possible in a small but distinct subset of patients, particularly in those who are very well controlled on relatively low doses administered at long intervals.Keywords
This publication has 27 references indexed in Scilit:
- Acromegaly pathogenesis and treatmentJCI Insight, 2009
- Guidelines for Acromegaly Management: An UpdateJournal of Clinical Endocrinology & Metabolism, 2009
- A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegalyClinical Endocrinology, 2007
- Primary Treatment of Acromegaly with Octreotide LAR: A Long-Term (Up to Nine Years) Prospective Study of Its Efficacy in the Control of Disease Activity and Tumor ShrinkageJournal of Clinical Endocrinology & Metabolism, 2006
- Biochemical evaluation of disease activity after pituitary surgery in acromegaly: a critical analysis of patients who spontaneously change disease statusClinical Endocrinology, 2006
- Primary medical therapy for acromegalyClinical Endocrinology, 2003
- Efficacy of the New Long-Acting Formulation of Lanreotide (Lanreotide Autogel) in the Management of AcromegalyJournal of Clinical Endocrinology & Metabolism, 2002
- Long-Term Effects of Depot Long-Acting Somatostatin Analog Octreotide on Hormone Levels and Tumor Mass in AcromegalyJournal of Clinical Endocrinology & Metabolism, 2001
- Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study [published erratum appears in J Clin Endocrinol Metab 1995 Nov;80(11):3238]Journal of Clinical Endocrinology & Metabolism, 1995
- Medical Treatment of Acromegaly with SMS 201-995, a Somatostatin Analog: A Comparison with Bromocriptine*Journal of Clinical Endocrinology & Metabolism, 1987